ストックスクリーナーアプリを入手
785.28
2.41%
-27.53
前日終値:
$812.81
開ける：
$797.52
24時間の取引高:
274.26K
Relative Volume:
0.82
時価総額：
$49.26B
収益：
$4.16B
当期純損益:
$1.29B
株価収益率:
40.10
EPS:
19.5837
ネットキャッシュフロー:
$734.26M
1週間 パフォーマンス:
-1.78%
1か月 パフォーマンス:
-1.99%
6か月 パフォーマンス:
-11.05%
1年 パフォーマンス:
+46.22%
1日の値動き範囲:
$789.99
$810.70
1週間の範囲:
$777.14
$840.67
52週間の値動き範囲:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
792.14 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
453.04 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
720.58 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.02 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.10 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-12-18 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 再開されました | Truist | Buy |
| 2025-09-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease - Benzinga
argenx stock gains after FDA expands MG treatment approval - Investing.com
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - ChartMill
RBC Capital maintains argenx stock price target at $890 on uptake potential - Investing.com Nigeria
ARGX.BR Stock Price, Quote & Chart | ARGENX SE (EBR:ARGX) - ChartMill
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 By Investing.com - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 - Investing.com
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com Canada
argenx posts 63% revenue growth on strong Vyvgart sales By Investing.com - Investing.com South Africa
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
argenx appoints Karen Massey as CEO, founder moves to chair - Investing.com
argenx to Present at BofA Securities 2026 Health Care Conference - ChartMill
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer - ChartMill
ARGX.BR Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SE (EBR:ARGX) - ChartMill
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN) - The Globe and Mail
argenx SE Stock Baskets | MEX:ARGXN - GuruFocus
argenx SE Stock Operating Data - GuruFocus
argenx SE (MEX:ARGXN) Stock News, Headlines & Updates - GuruFocus
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Argenx SE stock (NL0010832176): Is its rare disease focus strong enough to unlock sustained U.S. gro - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's momentum strong enough to unlock new upside? - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's expansion strong enough to unlock new upside? - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's rare disease dominance strong enough to unlock new upsi - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. momentum strong enough to unlock new upside? - AD HOC NEWS
argenx SE (MEX:ARGXN) Competitors 2026 - GuruFocus
Who's Buying or Selling argenx SE (MEX:ARGXN) Stock Today? - GuruFocus
argenx SE (MEX:ARGXN) Stock Price, Trades & News - GuruFocus
argenx SE (MEX:ARGXN)Valuation Measures & Financial Statistics - GuruFocus
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Avalo Therapeutics (AVTX) - The Globe and Mail
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. expansion strong enough to unlock new upside? - AD HOC NEWS
Argenx shares see TD Cowen reiterate Buy on Vyvgart strength By Investing.com - Investing.com South Africa
Argenx shares see TD Cowen reiterate Buy on Vyvgart strength - Investing.com
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. dominance now the key growth lever? - AD HOC NEWS
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026 By Investing.com - Investing.com South Africa
Argenx Leads Turnover Charts with $250 Million in Trades, Concealing a Slight Decline During Sector Shifts - Bitget
How is argenx (ARGX) Stock performing in 2026 | ARGX Q4 Earnings: Beats Estimates by $1.77Share Dilution - Newser
ARGX Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Stocks Showing Improved Relative Strength: argenx ADR - Investor's Business Daily
Target Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx SE Stock: Biotech Leader in Autoimmune Therapies Driving Investor Interest with Strong Growth - AD HOC NEWS
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Is Viridian Therapeutics Stock Falling Monday? - Sahm
argenx SE (HAM:1AEA) Stock Price, Trades & News - GuruFocus
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Stock Faces Pressure Amid Pipeline Setbacks and Market Volatility in Biotech Sector - ad-hoc-news.de
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
2.06%
1.43%
大文字化:
|
ボリューム (24 時間):